Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Change in Account Payables (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Change in Account Payables data on record, last reported at $487000.0 in Q4 2025.

  • For Q4 2025, Change in Account Payables fell 47.69% year-over-year to $487000.0; the TTM value through Dec 2025 reached $176000.0, up 130.99%, while the annual FY2025 figure was $176000.0, 130.99% up from the prior year.
  • Change in Account Payables reached $487000.0 in Q4 2025 per VRCA's latest filing, up from -$736000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.5 million in Q2 2023 and bottomed at -$1.4 million in Q2 2024.
  • Average Change in Account Payables over 5 years is $98400.0, with a median of $69500.0 recorded in 2021.
  • Peak YoY movement for Change in Account Payables: surged 1580.0% in 2022, then crashed 971.15% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at -$25000.0 in 2021, then soared by 1580.0% to $370000.0 in 2022, then surged by 56.22% to $578000.0 in 2023, then soared by 61.07% to $931000.0 in 2024, then tumbled by 47.69% to $487000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $487000.0 in Q4 2025, -$736000.0 in Q3 2025, and $878000.0 in Q2 2025.